Akari Therapeutics Stock (AKTX) Rises After Patent Filing for Novel Cancer Therapy

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-17 21:01:02

BTCCSquare news:

Akari Therapeutics' shares surged 6% to $0.80 following the filing of a provisional patent application for its innovative antibody drug conjugate platform. The biotech firm's targeted cancer treatment disrupts alternative splicing—a fundamental cellular process—rather than focusing on single mutations, potentially broadening its therapeutic reach.

The patent application covers Akari's PH1-delivering system, which hijacks cancer cells' protein synthesis mechanisms. Market observers note the stock's rebound contrasts sharply with its 35% decline over the previous quarter, suggesting renewed investor confidence in the company's proprietary technology.

By:

Log in to Reply

Baidu Surges 16% on AI Chip Optimism as Arete Upgrades to Buy

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.